Arcutis Biotherapeutics, Inc. ARQT Business Segments — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — interest expense, nonoperating of $4.37M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating increased by 46.5% year-over-year, from $2.98M to $4.37M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating?
- Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s business segments — interest expense, nonoperating has grown at a -8.3% compound annual growth rate (CAGR), from $15.65M to $12.08M.
- What does business segments — interest expense, nonoperating mean?
- Captures the costs associated with the segment's debt obligations and financing activities that are not related to core operations. This metric highlights the financial burden of the segment's capital structure.